POINT Biopharma USA Inc.
FDA inspection history in Indianapolis, Indiana, 2024
- 1
- Form 483
Every document, by year
- Form 483
2024: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2024One Form 483, at Indianapolis, Indiana.
Cited most
Across all POINT Biopharma USA observations on file
- 21 CFR 211.84Testing and approval or rejection of components, drug product containers, and closures1
The complete POINT Biopharma USA file.
All 1 documents as original PDFs. For supplier audits, diligence and inspection prep.
Sites
Indianapolis, Indiana
One Form 483 · 2024 · 1 observation
Latest: Form 483, Jun 7, 2024 →
Documents
1 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2024-06-07 | 483 Form 483 | Indianapolis, Indiana | 1 | $99 |
FEI number 3017226344 · most recent document Jun 7, 2024
About POINT Biopharma USA Inc.
How many FDA Form 483s has POINT Biopharma USA Inc. received?
FDA Intel has 1 Form 483 on file for POINT Biopharma USA Inc.; the most recent is dated Jun 7, 2024.
When was POINT Biopharma USA Inc. last inspected by FDA?
The most recent FDA inspection document on file for POINT Biopharma USA Inc. is a Form 483 dated Jun 7, 2024, for the site in Indianapolis, Indiana.
What did FDA cite at POINT Biopharma USA Inc.?
The regulations cited most in the observations on file for POINT Biopharma USA Inc. are 21 CFR 211.84 (Testing and approval or rejection of components, drug product containers, and closures), 1 time.